Tag: BioSpace

Pictured: European Medicines Agency sign on building/iStock, Lubo Ivanko Following in the footsteps of U.K. and U.S. regulators, a European Medicines Agency committee on Thursday endorsed Vertex Pharmaceuticals and CRISPR Therapeutics’ Casgevy, which is intended for the treatment of sickle cell disease and transfusion‑dependent beta thalassemia in Europe.  EMA’s Committee…

Pictured: Two professionals shaking hands/iStock, fizkes Editas Medicine and Vertex Pharmaceuticals have forged a $50 million deal for a licensing agreement of Editas’s Cas9 technology. In an announcement on Wednesday, Editas said Vertex will get a non-exclusive license the gene editing tech for use in medicines that target the BCL11A…

Pictured: Stack of coins with trading graph/iStock, KanawatTH Biotech startup Tome Biosciences emerged from stealth on Tuesday armed with with $213 million in funding from prominent investors and technology licensed from from the Massachusetts Institute of Technology. Tome raised $213 million in Series A and B funding rounds from several investors,…

Pictured: Regeneron logo on a light brown building/Shutterstock, Lev Radin Regeneron has lifted the curtain on Phase II data for odronextamab, which it is investigating in patients with relapsed/refractory follicular lymphoma. Regeneron’s investigational CD20xCD3 bispecific antibody results were announced Sunday at the American Society of Hematology annual meeting. Regeneron said…

As a business journalism publication, BioSpace doesn’t get many news days like we had on Friday. Not just one but two major FDA approvals happened simultaneously for the first cell-based gene therapies to treat patients with sickle cell disease.    While the FDA’s decision regarding Vertex Pharmaceuticals and CRISPR Therapeutics’…

Pictured: FDA headquarters/iStock, Grandbrothers Following in the footsteps of its U.K. counterpart, the FDA on Friday approved the first-ever CRISPR-based gene editing therapy in the form of Vertex Pharmaceuticals and CRISPR Therapeutics’ Casgevy (exagamglogene autotemcel) for sickle cell disease, while also granting approval to bluebird bio’s lovo-cel, which will carry…

Pictured: An hourglass connected by strands of DNA/Nicole Bean for BioSpace Updated upon FDA approval exa-cel. The FDA today signed off on Vertex Pharmaceuticals and CRISPR Therapeutics’ exa-cel for sickle cell disease. And earlier this fall, the regulator greenlit the first U.S.-based in vivo base editing trial, run by Verve Therapeutics. These actions…

Pictured: A collage of medical notes and anatomy/Nicole Bean for BioSpace With all the recent headlines being made in genetic medicine, a presentation from Turn Biotechnologies announcing the first successful in vivo delivery of messenger RNA to the skin with no off-target effects flew largely under the radar. While Turn…

Pictured: A sign in front of FDA headquarters/iStock, JHVEPhoto The FDA has three target action dates on the books during the next two weeks, including one potentially industry-transforming decision for a CRISPR-based gene therapy. Vertex, CRISPR Eye Landmark Gene Therapy Approval In one of the year’s most highly anticipated decisions,…

Published: Nov 22, 2023 By Greg Slabodkin, Lori Ellis, Heather McKenzie Last Thursday, the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) ⁠approved CRISPR/Cas9⁠ gene-edited therapy exagamglogene autotemcel (exa-cel). Will the FDA follow suit? What can patients expect the price tag to…

Bayer announced earlier this week it has stopped the OCEANIC-AF phase 3 clinical trial investigating the factor FXIa inhibitor asundexian for the agent’s lack of efficacy compared to apixaban, a factor Xa inhibitor, in patients with atrial fibrillation (AF) at risk for stroke or systemic embolism.1 The decision to halt…

Medication focuses on the acute treatment of migraines. AbbVie announced results published in The Lancet evaluating the efficacy, safety, and tolerability of Ubrelvy (ubrogepant) 100 mg for the acute treatment of migraine when administered during the prodrome of a migraine attack. According to a Phase 3 prodrome study, results indicated…

Pictured: Illustration of a CRISPR/Cas9 system on a DNA strand/iStock, Artur Plawgo This past June marks the 11th anniversary of the development of CRISPR as a genome-editing tool, which earned Jennifer Doudna and Emmanuelle Charpentier the 2020 Nobel Prize in Chemistry. CRISPR-Cas9 technology was revealed to the world in the journal…

Pictured: An illustration of a CRISPR/Cas9 system attached to a DNA strand/iStock, Meletios Verras The U.K.’s Medicines and Healthcare products Regulatory Agency on Thursday granted Vertex Pharmaceuticals and CRISPR Therapeutics conditional marketing authorization for their CRISPR/Cas9 gene-edited therapy exagamglogene autotemcel, now to carry the brand name Casgevy, for the treatment of…

Pictured: Gloved hand holding a specimen vial for an LDL-C test/iStock, Md Saiful Islam Khan  Verve Therapeutics on Sunday unveiled early data from the Phase Ib heart-1 trial of its next-generation gene editing therapy VERVE-101, demonstrating strong cholesterol reductions in patients with heterozygous familial hypercholesterolemia (HeFH). The results, presented at the…

Lumasiran (Oxlumo) demonstrated durable reductions in plasma oxalate levels among patients with advanced primary hyperoxaluria type 1 (PH1) with severe renal impairment, including those on dialysis, according to 24-month follow-up data from the phase 3 ILLUMINATE-C trial (NCT04152200). The study is still ongoing as data are being collected up to…

Pictured: Three doctors holding their thumbs up/iStock, andrei_r The FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee on Tuesday agreed that Vertex Pharmaceuticals had sufficiently demonstrated the safety of its investigational sickle cell disease gene-edited therapy exagamglogene autotemcel (exa-cel). Still, the panel of external experts did indicate that Vertex and its…

Pictured: Illustration of a CRISPR/Cas9 system on a DNA strand/iStock, Artur Plawgo Ahead of a Tuesday advisory committee meeting, FDA staff have called into question the safety risk testing for Vertex Pharmaceuticals and CRISPR Therapeutics’ investigational sickle cell disease therapy exagamglogene autotemcel (exa-cel). In their briefing document for the adcomm, the…

Since they were discovered around three decades ago, molecular glues have come a very long way as a therapeutic option for several different disease areas, including cancer and neurodegenerative disorders. Now, there are a rising number of molecular glue companies hoping to show clinical success with their candidates.  The term…

AbbVie’s Genomics Research Center Computational Genomics is looking for a highly motivated computational biologist (Senior Scientist II, Bioinformatics) to join a team of bioinformatics scientists investigating aging and age-related diseases. AbbVie’s GRC is a center of excellence for bioinformatics, functional genomics, and human genetics. The GRC works across all R&D…

(Image Credit: ©Tartila – Adobe.Stock.com) The China National Medical Products Administration (NMPA) has approved Skyline Therapeutics’ Investigational New Drug (IND) application for SKG0106. This new treatment compound is a one-time AAV gene therapy for the treatment of neovascular age-related macular degeneration (nAMD) delivered intravitreally.1 According to the company’s press release,…

At Lilly, we unite caring with discovery to make life better for people around the world. We are a global healthcare leader headquartered in Indianapolis, Indiana. Our 35,000 employees around the world work to discover and bring life-changing medicines to those who need them, improve the understanding and management of…

The Genomics Research Center (GRC) is a center of excellence for genetics and genomics that supports both Discovery and Development. The GRC plays an integral role towards our goal of developing extraordinary genetics and genomics research, focusing on finding the right targets and helping us better understand not only human…

GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale…

Pictured: Finger pressing pause button/iStock, cagkansayin Relay Therapeutics announced plans Thursday to shift gears, pausing its push for rare cancer and switching focus to the larger tumor-agnostic market. The Boston-based biotech is pointing to the Inflation Reduction Act as a driving factor of its decision.  Relay’s FGFR2 inhibitor has been…

United States – California – Foster City Gilead Sciences, Inc. is a research-based bio-pharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. With each new discovery and investigational drug candidate, we seek to improve the care of patients living with life-threatening diseases around the…

The Toxin Innovation Group at AbbVie seeks a highly skilled and motivated bioinformatics scientist (Senior Scientist I, bioinformatics) focused on novel neurotoxin discovery research. The Senior Scientist will play an integral role in our research team, contributing to the generation, analysis and interpretation of genomic data to advance our understanding…

Pictured: Illustration of a CRISPR-Cas9 system conducting edits on a DNA strand/iStock, Meletios Verras Regeneron on Tuesday announced it is expanding an existing collaboration agreement with Intellia Therapeutics to develop CRISPR-based gene editing therapies targeting neurological and muscular diseases. The expanded agreement will combine Regeneron’s proprietary delivery systems and antibody-targeted adeno-associated…

Job ID: req3751Employee Type: exempt full-timeDivision: Cancer Research Technology ProgramFacility: NIHLocation: NIH Campus 9000 Rockville Pike, Bethesda, MD 20892 USAThe Frederick National Laboratory is a Federally Funded Research and Development Center (FFRDC) sponsored by the National Cancer Institute (NCI) and operated by Leidos Biomedical Research, Inc. The lab addresses some…

Pictured: Illustration of a CRISPR-Cas9 system/iStock, Artur Plawgo A paper published on Thursday in The New England Journal of Medicine suggests that the potential cause of the 2022 death of a Duchenne muscular dystrophy patient was due to an innate immune reaction triggered by the high dose of recombinant adeno-associated virus…

Pictured: AbbVie corporate office in Illinois/iStock, vzphotos AbbVie has walked away from its collaboration and license agreement with Caribou Biosciences, the Berkeley-based biotech announced in an SEC filing posted Tuesday.   AbbVie’s decision was a strategic move by the company “and was unrelated to Caribou’s performance under the agreement or…

The global Metagenomic Market , with a valuation of USD 1.41 billion in 2022, is poised to expand significantly, reaching USD 5.57 billion by 2032, and demonstrating a robust revenue Compound Annual Growth Rate (CAGR) of 16.5% over the forecast period. The primary driver behind this market’s revenue surge is…

Senior Director of Bioinformatics at Southern ResearchGeneral SummarySouthern Research (SR) is at a pivotal moment in its 80-year history. At the start of 2022, SR launched a new strategic plan focused on translational research in the life sciences. SR intends to invest over $150 million in this new strategy, including…

Why join Freenome?Freenome is a high-growth biotech company developing tests to detect cancer using a standard blood draw. To do this, Freenome uses a multiomics platform that combines tumor and non-tumor signals with machine learning to find cancer in its earliest, most-treatable stages.Cancer is relentless. This is why Freenome is…

Job ID: req3672Employee Type: exempt full-timeDivision: Cancer Research Technology ProgramFacility: Frederick: ATRFLocation: 8560 Progress Dr, Frederick, MD 21701 USAThe Frederick National Laboratory is a Federally Funded Research and Development Center (FFRDC) sponsored by the National Cancer Institute (NCI) and operated by Leidos Biomedical Research, Inc. The lab addresses some of…

Pictured: Illumina sign in San Diego/iStock, Georgejason After months of upheaval, Illumina named Jacob Thaysen its new CEO Tuesday, replacing Francis deSouza who stepped down in June after losing a proxy fight with billionaire activist investor Carl Icahn.  Thaysen, the former senior vice president of Agilent Technologies and president of…

Since 2013, AbbVie has expanded its commitment to the San Francisco Bay Area with the consolidation of three Bay Area facilities to a new Bay Area headquarters in South San Francisco. AbbVie employees in the Bay Area drive AbbVie’s research-based, innovation driven missions in healthcare. Specifically, Bay Area employees bring…

GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale…

Pictured: Novo Nordisk flag hangs from a pole/iStock It’s been a big week for Danish drugmaker Novo Nordisk. The company announced Tuesday that its obesity drug Wegovy cut the risk of major cardiovascular complications by 20% in a landmark 17,500-patient trial, which was the first to show that such medication…

Job ID: req3664Employee Type: exempt full-timeDivision: Bioinformatics and Computational ScienceFacility: NIHLocation: NIH Campus 9000 Rockville Pike, Bethesda, MD 20892 USAThe Frederick National Laboratory is a Federally Funded Research and Development Center (FFRDC) sponsored by the National Cancer Institute (NCI) and operated by Leidos Biomedical Research, Inc. The lab addresses some…

The presenter, Jeffrey S. Heier, MD, Director of the Retina Service and Retina Research, Ophthalmic Consultants of Boston, and an investigator in ARCHER will deliver the data on July 30, 2023 at 9:00 am PT. (Image Credit: ©Kasto – Adobe.Stock.com) Annexon, Inc. will present results from the ongoing ARCHER Phase…

A phase 3 clinical program has been initiated for a potential monotherapy for the treatment of major depressive disorder (MDD). The monotherapy treatment is navacaprant (NMRA-140), an oral, once-daily, 80 mg, novel kappa opioid receptor (KOR) antagonist designed to modulate the dopamine and reward processing pathways. Navacaprant showed statistically significant…

Job Details Bioinformatics Analyst II/III Job ID: req3605 Employee Type: exempt full-time Division: Bioinformatics and Computational Science Facility: NIH Location: NIH Campus 9000 Rockville Pike, Bethesda, MD 20892 USA The Frederick National Laboratory is a Federally Funded Research and Development Center (FFRDC) sponsored by the National Cancer Institute (NCI) and…

Pictured: CRISPR-Cas9 genome editing enzyme/iStock, Artur Plawgo Hereditary angioedema patients treated with Intellia’s NTLA-2002—an in vivo CRISPR-Cas9 therapy— had an average 95% reduction in the sudden, debilitating bouts of swelling that are a hallmark of the disease, with some patients remaining attack-free for more than a year, according to updated Phase…

Job Details Job Type Full-time We are seeking a motivated and experienced bioinformatics developer to build an AI driven platform focused on analysis of synthetic DNA and mRNA. This will require collecting and analyzing very large data sets built from a variety of sources including sequencing, RNA folding and structure…

Job ID: req3312Employee Type: exempt full-timeDivision: Bioinformatics and Computational ScienceFacility: NIHLocation: NIH Campus 9000 Rockville Pike, Bethesda, MD 20892 USAThe Frederick National Laboratory is a Federally Funded Research and Development Center (FFRDC) sponsored by the National Cancer Institute (NCI) and operated by Leidos Biomedical Research, Inc. The lab addresses some…

About Acrivon Therapeutics, Inc.Acrivon (NASDAQ: ACRV) is a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing Acrivon’s proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics, or AP3. The AP3 platform…

GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale…

North American region is the largest shareholder in the global genome editing market, the increasing prevalence of genetic disorders and adoption of advanced gene therapy for the treatment of chronic diseases is expected to drive the market in the country during 2021-2028. Pune, India, June 23, 2023 (GLOBE NEWSWIRE) —…

The Insight Partners North American region is the largest shareholder in the global genome editing market, the increasing prevalence of genetic disorders and adoption of advanced gene therapy for the treatment of chronic diseases is expected to drive the market in the country during 2021-2028. Pune, India, June 23, 2023…

Pune, India, June 23, 2023 (GLOBE NEWSWIRE) — According to our latest study on “Genome Editing Market Size Report, Forecast to 2028 – COVID-19 Impact and Global Analysis – by Technology, Application, and End User,” the market size is projected to reach $16.98 billion by 2028; which was valued at…

Pictured: T cells attacking and killing cancer cells / iStock, Meletios Verras Four weeks after competitor AbbVie’s bispecific antibody for lymphoma was approved, the FDA Thursday gave the nod to Roche Group member Genentech’s BsAb for relapsed or refractory diffuse large B-cell lymphoma.   A head-to-head competition is brewing between both companies’…

Pictured: An elderly man with his hand over his heart/iStock, Rawpixel Verve Therapeutics secured a $60 million investment from Eli Lilly for its “one-and-done” cardiovascular gene editing program, which aims to revolutionize the treatment of heart disease. The collaboration comes at a time when other major players in the industry, including Amgen…

The Genomics Research Center (GRC) is a center of excellence for genetics and genomics that supports both Discovery and Development. The GRC plays an integral role towards our goal of developing extraordinary genetics and genomics research, focusing on finding the right targets and helping us better understand not only human…

AbbVie’s Genomics Research Center Computational Genomics is looking for a highly motivated computational biologist (Senior Scientist I/II, Bioinformatics) to join a team of bioinformatics scientists investigating aging and age-related diseases. AbbVie’s GRC is a center of excellence for bioinformatics, functional genomics, and human genetics. The GRC works across all R&D…

Duchenne muscular dystrophy continues to be a challenging disease to tackle, taking down another promising late-stage investigational drug. FibroGen reported that its phase 3 LELANTOS-1 clinical trial, which examined the effects of pamrevlumab in non-ambulatory patients with Duchenne muscular dystrophy (DMD), failed to meet its primary end point.1 Although safe…

Job Details Acrivon is a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing Acrivon’s proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics, or AP3. The AP3 platform enables the creation…

DNA sequencing is a method that determines the order of the four nucleotide bases, namely, adenine (A), thymine (T), guanine (G), and cytosine (C), that form a DNA molecule. In this article, AZoLifeSciences offers a comprehensive guide to DNA Sequencers. Image Credit: Blue Andy/Shutterstock.com In a DNA double helix, nucleotide bases…

Pictured: shRNA sense and antisense sequences/iStock, Love Employee The recent FDA approval of Biogen’s Qalsody for superoxide dismutase 1 (SOD1)–ALS highlighted the potential for antisense oligonucleotides in central nervous system diseases. But the recent failure of Wave Life Sciences’ WVE-004 in C9orf72–ALS also showed their limitations. Antisense oligonucleotides (ASOs) are…

Pictured: Doctor holding tablet/iStock, Ridofranz As mass layoffs in the tech industry continue, biopharma companies are taking advantage of the opportunity to hire employees who may be looking to make a switch to the life sciences.  Though layoffs are never something to celebrate, for those looking to move into biopharma, the…

Pictured: Front of FDA headquarters/Grandbrothers/Adobe Stock Friday, AbbVie and Genmab won the FDA’s greenlight for their bi-specific T-cell engager epcoritamab-bysp, now with the brand name Epkinly, for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adults. Epkinly was approved under the regulator’s accelerated pathway and is…

Pictured: Illustration of CRISPR-Cas9 editing DNA / iStock, Artur Plawgo Tuesday, Jennifer Doudna-founded Scribe Therapeutics and Eli Lilly subsidiary Prevail entered into a strategic collaboration to develop CRISPR-based genetic medicines for neurological and neuromuscular indications. Under the terms of the agreement, Prevail will make a $75 million upfront payment and equity…

Transmition Electron microscopy of an epithelial cell showing mitochondria/courtesy of Dlumen/iStock  They’re the powerhouses of the cell, generating energy for nearly every organ in the body. But when mitochondria are dysfunctional, the resulting power outage can cause devastation for children and adults with rare and ultra-rare diseases. One rare mitochondrial…

The road to business heaven is paved with lucky decisions and loud bumps. Elon Musk, one of the richest men on the planet, knows it well. Before seeing himself elevated to the top of Forbes’ multimillionaire Olympus —exactly what step he occupies depends on the fluctuations of his fortune— the…

Pictured: Illustration showing blood vessel with normal and sickled red blood cells / Adobe, tussik bluebird bio announced Monday that it has submitted a Biologics License Application (BLA) for lovotibeglogene autotemcel (lovo-cel), a gene therapy treatment for sickle cell disease (SCD). Bluebird is seeking approval to sell lovo-cel as a…

Pictured: Genentech sign in front of building/Sundry Photography/Adobe Stock The FDA has approved Roche-subsidiary Genentech’s Polivy (polatuzumab vedotin-piiq), as part of a five-drug regimen, for the first-line treatment of patients with diffuse large B-cell lymphoma (DLBCL), the company announced Thursday. The treatment regimen combines Polivy with Rituxan (rituximab), cyclophosphamide, doxorubicin and prednisone…

Pictured: a scientist working on machine learning models/gorodenkoff/iStock As the number of employees laid off in the tech industry continues to grow, biopharma companies are increasingly recruiting talent who wish to transfer their skills to the life sciences.  Specifically, those with skills in artificial intelligence (AI) and machine learning (ML)…

PRESS RELEASE Published April 11, 2023 The biotechnology market is a rapidly growing industry that combines biology, chemistry, and engineering to develop innovative products and services for a range of applications in healthcare, agriculture, food production, and the environment. Here are some key points about the biotechnology market: Key players:…

Pictured: Exelixis headquarters/Company courtesy Farallon Capital Management is waging a proxy battle with Exelixis over R&D spending. The hedge fund issued a letter to the company’s board of directors on Wednesday. Farallon has a 7.2% stake in the genomics-based drug discovery company, making it the largest active shareholder, according to…

Pictured: Intellia office building with logo/company courtesy With several recent milestones, Intellia Therapeutics is setting a solid foundation for gene editing in rare diseases like hereditary angioedema (HAE) and transthyretin (ATTR) amyloidosis with an eye toward broader patient populations. Laura Sepp-Lorenzino, Ph.D., EVP and chief scientific officer, joined Intellia in…

Pictured: Seamless Therapeutics’ Anne-Kristin Heninger, CEO and Felix Lansing, CSO/company courtesy Seamless Therapeutics launched Wednesday with $12.5 million in seed financing to develop its programmable recombinases for gene editing. Seamless’ platform of reprogrammed site-specific recombinases gives a range of options for gene editing, including inversion, excision, exchange and insertion of small to large…

Catherine Stehman-Breen, CEO, Chroma Medicine/company courtesy Number 11 on BioSpace’s NextGen Bio “Class of 2023”, Chroma Medicine snagged $135 million in Series B financing amidst a challenging economic landscape. Google Ventures (GV) led the Massachusetts-based biotech’s successful funding round, announced Wednesday, along with a slew of new and existing investors. Chroma…

Akin Akinc, Ph.D., CEO, Area Therapeutics/company courtesy An Alynylam vet and CRISPR big wig have joined forces against one of genetic medicine’s biggest inhibitions – delivery, as Aera Therapeutics emerged from stealth mode Thursday to take on the challenge. Fueled by major investors ARCH, GV and Lux, the fledgling biotech…

PRESS RELEASE Published February 2, 2023 The pet food packaging market is projected to reach value of USD 13.27 Billion by 2027, according to a current analysis by Emergen Research. This growth of the market for pet food packaging can be attributed to high rate of pet adoption and growing trend of…

Images for Biotechnology Careers Biotechnology Careers: In-Demand Jobs Shaping Our Future ICAR-NRCB Recruitment 2020 – BSc Microbiology & Biotechnology Job Govt RGCB Research Jobs – Biotechnology & Bioinformatics JRF Position Biotech Jobs | CT19 Biotechnology Job Outlook | A Career in High Demand 9 of the Best Biotechnology Careers For…

Rise in Black Fungus infection hints at the necessity to monitor and control diabetes Researchers from Rice University, Houston, have developed a new mechanism that allows the editing of multiple DNA sites all at once, with the help of CRISPR/Cas9 technology. This new mechanism, referred to as the ‘drive-and-process’ or…

Job DescriptionJob SummaryThis position will be responsible for computational analyses on our novel mRNA vaccine platform to characterize novel antigens and evaluate subsequent vaccine responses. This position will work to analyses complex datasets and assist in experimental design to ensure rigorous statistical integrity. This position work collaboratively with other computational…

We are currently searching for a Bioinformatics Scientist to provide support services to satisfy the overall operational objectives of the Center for Alzheimer’s and Related Dementias, National Institute on Aging. The primary objective is to provide services and deliverables through performance of support services. This opportunity is full-time, and it…

Please be aware that, as a condition of employment, proof of COVID vaccination is required for all U.S.-based employees (subject to limited exceptions).Title: Bioinformatics Scientist Location: San Diego, CA, or Menlo Park, CA , or Remote Position Summary An emerging leader in next-generation sequencing technology is seeking a driven Bioinformatics…

We are currently searching for a Bioinformatics Python Developer to provide support to the National Institutes of Health (NIH). This opportunity is a permanent, full-time position with MSC, and it is on-site in Rockville, MD. Duties & Responsibilities The role will be responsible for developing and extending software solutions for…

Web Resources Virtualab Home AgricultureBioinformaticsBiophysicsCancerCareerCellBiologyDevelopmentEcologyEducationFunGeneticsGenomicsHealthLabMicrobiologyMolecularMoleculeNeurosciencesPaleontologyPlantPolicySociety Instructionsupplierprotocol… Career Links AACC Onlin – American Association of Clinical Chemistry career center. Academia : Job listings in academia, major US universities, and positions in Australia, Canada, and Europe. Academic Employment Network: US academic positions. Academic network : Jobs in higher education. Academic, Physician…

We’re hiringBioinformatics Scientists with strong backgrounds in database development, management and analysis as they relate to human health and disease biomarkers, with the goal of improving disease prediction and prevention. With ICR, You’ll Get To Design, build, test and refine multiple large biomarker databases in collaboration with multiple ICR teams…

Courtesy Intellia Therapeutics Intellia Therapeutics is celebrating another first today as the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for NTLA-5001, its first wholly-owned ex vivo CRISPR genome editing candidate. NTLA-5001 is being developed for the treatment of acute myeloid leukemia (AML). Intellia…

Join a Legacy of Innovation 110 Years and Counting!Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific…

more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines…

Photo courtesy of Intellia Therapeutics Sports fans know that nothing is better for the chemistry of a team than winning, and on the CRISPR field, Intellia Therapeutics is on a winning streak.    On June 26, Intellia set the biotech world on fire, announcing the first-ever clinical data supporting the safety…